Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8499602 | 0.83 | LMNA (0.59) | HTR2ATAAR1HTR2CPOLBL3MBTL1 | |
| SCHEMBL5297130 | 0.83 | CYP3A4 (0.47) | HTR2AHTR2CMAPTLMNATP53 | |
| SCHEMBL30073419 | 0.80 | LMNA (0.46) | HTR2ATAAR1HTR2CPOLBL3MBTL1 | |
| SCHEMBL17749691 | 0.80 | LMNA (0.46) | HTR2ATAAR1HTR2CPOLBL3MBTL1 | |
| SCHEMBL3134566 | 0.80 | HTR2A (0.43) | HTR2AHTR2CMAPTNPSR1HTR2B | |
| SCHEMBL23326154 | 0.78 | HTR2A (0.51) | HTR2ATAAR1HTR2CPOLBL3MBTL1 | |
| SCHEMBL29775360 | 0.78 | HTR2A (0.51) | HTR2ATAAR1HTR2CPOLBL3MBTL1 | |
| SCHEMBL298224 | 0.78 | POLB (0.59) | HTR2ATAAR1HTR2CPOLBL3MBTL1 | |
| SCHEMBL13169383 | 0.75 | LMNA (0.53) | HTR2ATAAR1HTR2CPOLBL3MBTL1 | |
| SCHEMBL5915652 | 0.74 | GAA (0.44) | POLBL3MBTL1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | claimed |
| US-20150025063-A1 | Antiparkinsonian Action of Phenylisopropylamines | UNIV DUKE (US) | 2015-01-22 | — | — | US | disclosed |
| US-8877802-B2 | Antiparkinsonian action of phenylisopropylamines | Duke Univerity (US) | 2014-11-04 | — | — | US | disclosed |
| EP-0746332-B2 | DNA ENCODING A HUMAN PANCREATIC POLYPEPTIDE RECEPTOR (Y4) AND USES THEREOF | LUNDBECK & CO AS H (DK) | 2010-05-19 | — | — | EP | disclosed |
| WO-2007016190-A2 | ANTIPARKINSONIAN ACTION OF PHENYLISOPROPYLAMINES | DUKE UNIVERSITY (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | disclosed |
| US-6913892-B1 | Method of obtaining compositions comprising Y4 specific compounds | H. LUNDBECK A/S (DK) | 2005-07-05 | — | — | US | disclosed |
| US-20030166066-A1 | DNA encoding a human serotonin receptor (5-HT4B) and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-09-04 | — | — | US | disclosed |
| US-6432655-B1 | BINDING AND 5-HT RECEPTORS AND GENE EXPRESSION | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-08-13 | — | — | US | disclosed |
| US-20020081661-A1 | DNA encoding 5-HT4 serotonin receptors and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-06-27 | — | — | US | disclosed |
| EP-0746332-B1 | DNA ENCODING A HUMAN NEUROPEPTIDE Y/PEPTIDE YY/PANCREATIC POLYPEPTIDE RECEPTOR (Y4) AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2000-02-09 | — | — | EP | disclosed |
| US-5985585-A | COMPETITIVE BINDING; DETECTION | SYNAPTIC PHARMACEUTICAL COORPORATION (US) | 1999-11-16 | — | — | US | disclosed |
| US-5976814-A | SCREENING DRUGS FOR RECEPTOR AGONIST ACTIVITY BY INCUBATING CHEMICAL WITH NONNEURONAL CELLS EXPRESSING HUMAN OR RAT Y4 RECEPTOR ON SURFACE; MEASURING SECOND MESSENGER RESPONSE IN PRESENCE AND ABSENCE OF COMPOUND | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| US-5958709-A | THIS INVENTION FURTHER PROVIDES METHODS FOR DETERMINING LIGAND BINDING, DETECTING EXPRESSION, DRUG SCREENING, AND TREATMENT INVOLVING THE HUMAN Y4 RECEPTOR. | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-09-28 | — | — | US | disclosed |
| US-5766879-A | ISOLATED NUCLEIC ACID MOLECULE ENCODING SEROTONIN RECEPTORS; DETERMINING LIGAND BINDING, DETECTING EXPRESSION, DRUG SCREENING | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0746332-A4 | DNA ENCODING A HUMAN NEUROPEPTIDE Y/PEPTIDE YY/PANCREATIC POLYPEPTIDE RECEPTOR (Y4) AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 1997-02-26 | — | — | EP | disclosed |
| EP-0746332-A1 | DNA ENCODING A HUMAN NEUROPEPTIDE Y/PEPTIDE YY/PANCREATIC POLYPEPTIDE RECEPTOR (Y4) AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-12-11 | — | — | EP | disclosed |
| US-5516653-A | GENETIC ENGINEERING | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-05-14 | — | — | US | disclosed |
| US-5472866-A | Genetic engineering | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1995-12-05 | — | — | US | disclosed |
| WO-1995017906-A1 | DNA ENCODING A HUMAN NEUROPEPTIDE Y/PEPTIDE YY/PANCREATIC POLYPEPTIDE RECEPTOR (Y4) AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1995-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | HTR2A 18/4885TAAR1 1075/4885HTR2C 44/4885 |
| US-20150025063-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | HTR2A 18/4885TAAR1 1075/4885HTR2C 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.